Black Diamond Therapeutics, Inc. Banner Image

Black Diamond Therapeutics, Inc. has reached its limit for free report views

Work for Black Diamond Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Black Diamond Therapeutics, Inc.

  • Ticker BDTX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Black Diamond Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in Cambridge, Massachusetts
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technologyMore platform, Mutation-Allostery-Pharmacology (MAP) platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. Black Diamond was founded by David M. Epstein, Ph.D. and Elizabeth Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began building the MAP platform and chemistry discovery engine.
Black Diamond Therapeutics, Inc.

Most Recent Annual Report

Black Diamond Therapeutics, Inc.
MOST RECENT 2021 Annual Report and Form 10K

Report Locked. Black Diamond Therapeutics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports